Kidney transplantation in two highly sensitized candidates after CAR T-Cell therapy
Por: Bhoj, Vijay G [Autor]
Colaborador(es): Kaminski, María | Zhao, Huiwu | Jackson, Kyle | Wang, Wei | Liu, Chengyang | Montgomery, Robert A | Ali, Nicole | Mangiola, Massimo | Spitzer, Thomas R | Safa, KassemTipo de material: 
TextoIdioma: Inglés Descripción: páginas: 2117-2125Tema(s): ENFERMEDAD RENAL CRÓNICA | TRASPLANTE DE RIÑÓN | CIRUGÍA GENERAL | CÉLULAS T | TRASPLANTE
En: The New England Journal of MedicineResumen: HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination (desensitization) have had inconsistent efficacy and have often failed to produce sustained reductions in anti-HLA antibodies in patients with the highest level of sensitization (calculated panel-reactive antibody score, ≥99.9%). We now report the results for the safety run-in cohort of a multicenter phase 1 clinical study evaluating the safety and efficacy of combined CD19-targeted and B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T cells in eliminating the cellular sources of preformed anti-HLA antibodies (ClinicalTrials.gov number, NCT06056102). Kidney transplantation was performed in two highly sensitized candidates after desensitization with the use of dual CAR T-cell therapy.
| Tipo de ítem | Ubicación actual | Colección | Signatura | Info Vol | Estado | Fecha de vencimiento | Código de barras |
|---|---|---|---|---|---|---|---|
Títulos de Revistas
|
Biblioteca Central ESSALUD | Colección General | NEJM (Navegar estantería) | Vol.394, No.21 (2026) | Disponible | NEJM011 |
HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination (desensitization) have had inconsistent efficacy and have often failed to produce sustained reductions in anti-HLA antibodies in patients with the highest level of sensitization (calculated panel-reactive antibody score, ≥99.9%). We now report the results for the safety run-in cohort of a multicenter phase 1 clinical study evaluating the safety and efficacy of combined CD19-targeted and B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T cells in eliminating the cellular sources of preformed anti-HLA antibodies (ClinicalTrials.gov number, NCT06056102). Kidney transplantation was performed in two highly sensitized candidates after desensitization with the use of dual CAR T-cell therapy.